| Japanese |
|---|
| Title | 131I-標識抗carcinoembryonic antigen (CEA) 抗体を用いた腫瘍陽性シンチグラフィ |
|---|
| Subtitle | 研究速報 |
|---|
| Authors | 伊藤和夫*, 秦温信**, 西信三***, 近藤征文**, 古舘正従*, 入江五朗**** |
|---|
| Authors(kana) | |
|---|
| Organization | *北海道大学医学部核医学講座, **第一外科学講座, ***第一生化学講座, ****放射線医学講座 |
|---|
| Journal | 核医学 |
|---|
| Volume | 22 |
|---|
| Number | 6 |
|---|
| Page | 901-905 |
|---|
| Year/Month | 1985/6 |
|---|
| Article | 報告 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「I. 緒言」放射性核種を標識した抗体を生体内に投与し, 悪性腫瘍の局在を体外からの計測にて検出しようとする放射免疫検出法 (radioimmunodetection : RID) は, 新しい癌診断法として注目されている. これまで幾つかの標識抗体の臨床応用が報告されているが, 消化器系の悪性腫瘍や肺癌, 乳癌, 甲状腺癌など様々な悪性腫瘍の腫瘍マーカーであるcarcinoembryonic antigen (CEA) に対する標識抗体を用いた報告が最も多い. 著者らもヌードマウスに移植したCEA産生腫瘍に対しては標識抗CEA抗体の高い腫瘍集積性を確認している. ポリクロナール (PoAb) およびモノクロナール (MoAb) 抗CEA抗体の臨床応用に関して報告する. 「II. 材料および方法」「1. 抗CEA抗体の作製」PoAbとMoAbの作製法は既に詳しく報告されているので, その概要についてのみ記載する. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | Radioimmunodetection, Anti-CEA antibody, Polyclonal, Monoclonal |
|---|
| English |
|---|
| Title | Radioimmunodetection Using 131I-Labeled Anti-Carcinoembryonic Antigen Antibodies for Human Malignant Tumor |
|---|
| Subtitle | |
|---|
| Authors | Kazuo ITOH*, Yoshinobu HATA**, Shinzou NISHI***, Masafumi KONDO**, Masayori FURUDATE*, Goro IRIE**** |
|---|
| Authors(kana) | |
|---|
| Organization | *Department of Nuclear Medicine, **First Department of Surgery, ***First Department of Biochemistry, ****Department of Radiology, University of Hokkaido, School of Medicine |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 22 |
|---|
| Number | 6 |
|---|
| Page | 901-905 |
|---|
| Year/Month | 1985/6 |
|---|
| Article | Report |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary] Radioimmunodetection using radiolabeled antibodies against tumor associated antigens proved to be noninvasive and useful for localization of malignant tumor. This was a preliminary study on positive delineation of malignant tumors with polyclonal (PoAb) and monoclonal (MoAb) anti-CEA antibodies performed in each 5 patients. Scintiphotos with both of antibodies delineated primary and/or metastatic foci in 8 patients out of 100nes. Detectability was equal with both of antibodies. However, MoAb showed higher tumor/nontumor ratio than PoAb. Subtraction processing as a contrast enhanced method for tumor localization was not needed with MoAb. In biodistribution except malignant foci and the thyroid, which was demonstrated due to inadequate premedication of Lugol, non-specific uptake of the radiotracer was noted to the liver with PoAb and to the bone marrow with MoAb, respectively. Blood counts of both antibodies showed diphasic disappearance. MoAb showed faster disappearance of blood radioactivity than that of PoAb. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | Radioimmunodetection, Anti-CEA antibody, Polyclonal, Monoclonal |
|---|